This House bill would strengthen the federal 340B drug discount program, which helps eligible safety-net hospitals, community health centers, and other covered providers buy outpatient drugs at reduced prices. The practical goal is to lower prescription drug costs for providers that serve low-income, uninsured, and underinsured patients, while preserving the savings these institutions use to support care. It was introduced in the House and sent to the committees with jurisdiction over health, tax, and education-related provisions.
What This Bill Does
- Strengthens the federal 340B drug discount program.
- Applies to covered providers such as safety-net hospitals and clinics.
- Aims to preserve discounted pricing on outpatient drugs.
- Would affect the way savings are used to support patient care and pharmacy access.
Who This Bill Affects
For patients who receive care from 340B-covered hospitals, clinics, or affiliated pharmacies, this bill could help sustain lower-cost access to outpatient medicines and the services that those savings support. If you use a safety-net provider, the bill could improve the provider’s ability to subsidize prescriptions, maintain pharmacy operations, and keep care available in high-need communities. For people who do not use these providers, the direct effect is likely limited.
See how this bill affects you — sign in for a personalized analysisWho Supports & Opposes This
- Safety-net hospitals and community health centers They argue the 340B program helps stretch limited budgets so providers can keep clinics open, offer discounted medicines, and finance care for uninsured and low-income patients. Stronger protections could stabilize services in communities with high unmet healthcare needs.
- Patients who rely on charity care or discounted prescriptions They generally benefit when providers have more financial room to absorb drug costs and maintain pharmacy access. Supporters say the program can reduce the chance that patients skip treatment because of price.
- Public health and community care advocates They view 340B as a tool for preserving access in medically underserved areas. From their perspective, strengthening the program helps protect local healthcare infrastructure that serves vulnerable populations.
- Drug manufacturers They often argue that stronger 340B rules can widen discounts beyond the original intent of the program and reduce transparency about whether savings reach patients. They also contend the program can increase pressure on drug revenues and distort pricing.
- Some independent pharmacies and pharmacy benefit stakeholders They may worry that changes to 340B can shift market power toward large hospital systems or create uneven reimbursement rules. Critics also raise concerns about whether savings are passed on in ways that benefit patients directly.
- Budget and fiscal watchdog groups They may argue that expanding 340B can raise healthcare spending indirectly if discounts are not tightly targeted or audited. Their concern is that the program can become a subsidy mechanism without strong accountability for patient benefit.
Key Implications
-
““strengthen the 340B drug discount program””
This indicates the bill would reinforce the existing federal program that lets eligible providers buy certain outpatient drugs at reduced prices. In practice, that can improve the financial footing of hospitals and clinics serving low-income or uninsured patients.
-
““340B drug discount program””
The program is centered on drug purchasing, not direct cash payments to patients. Its real-world effect depends on whether covered providers use the savings for lower drug costs, expanded services, or other safety-net operations.
-
““Referred to the Committee on Energy and Commerce””
That committee referral shows the bill is being handled through the House health-policy process, where the key program rules would be examined. Additional referral to tax and education committees suggests the bill may touch hospital financing and provider rules beyond healthcare alone.
Official Source & Bill Facts
BillBoard checks this page against public Congress.gov metadata, then adds plain-English analysis where available.
- Bill
- HR 9599
- Congress
- 119th Congress
- Official title
- To strengthen the 340B drug discount program.
- Policy area
- Healthcare
- Latest action
- Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (July 6, 2026)
- Last updated
- July 7, 2026
Latest Status
July 6, 2026
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Related Bills
Browse more Healthcare bills in Congress →
Take Action
Get more from BillBoard
Free tools to understand, respond to, and track this bill.
Ask AI about this billData sourced from api.congress.gov.